Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clene Inc (NQ: CLNN )

1.170 +0.010 (+0.86%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 23, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 182,769
Open 1.160
Bid (Size) 1.150 (31)
Ask (Size) 1.190 (5)
Prev. Close 1.160
Today's Range 1.140 - 1.190
52wk Range 0.8700 - 5.130
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Clene's Return On Capital Employed Overview
 
Via Benzinga
The Latest Analyst Ratings for Clene
 
Via Benzinga

Performance

YTD
+23.14%
+23.14%
1 Month
-2.50%
-2.50%
3 Month
+15.84%
+15.84%
6 Month
-58.95%
-58.95%
1 Year
-60.07%
-60.07%

More News

Read More
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2023
Via Benzinga
Clene's Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression
Via Benzinga
Clene: Still in the Running for ALS
Via PR Distribution
Topics Death
Exposures Death Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Clene Shares Move Higher On Encouraging Data From Multiple Sclerosis Candidate
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Clene Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8® Treatment Improved Brain Neuronal Structural Integrity
From Clene Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Clene Nanomedicine Announces Participation in Renmark Virtual Non-Deal Roadshow Series on January 18 and January 23
From Clene Inc.
Via Globe NewsWire
Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial
Via Benzinga
Clene Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg
From Clene Inc.
Via Globe NewsWire
Clene Announces Closing of $5 Million Debt Facility from the State of Maryland
From Clene Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
VISIONARY-MS Trial Results Featured in Platform Presentation at PACTRIMS 2022: CNM-Au8® Demonstrated Global Neurological Improvement in Stable MS Patients as Adjunct to Background Disease Modifying Therapies
From Clene Inc.
Via Globe NewsWire
Clene: Q3 Earnings Insights
Via Benzinga
Clene Reports Third Quarter 2022 Financial Results and Recent Operating Highlights
From Clene Inc.
Via Globe NewsWire
Clene Announces $10.8 Million Registered Direct Offering and $5 Million Debt Facility from the State of Maryland
From Clene Inc.
Via Globe NewsWire
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
New Drugs And Therapies Are Giving MS And ALS Sufferers New Hope
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.